Back

Esophageal adenocarcinoma relapse after chemoradiation is dominated by a basal-like subtype

Hoppe, S.; Noseir, S.; Yazbeck, A.; Zaburannyi, N.; Grossbach, J.; Lyu, S. I.; Camacho, O. V.; Mueller, S.; Gebauer, F.; Richartz, V.; Holz, B.; Berg, J.; Achter, V.; Altmueller, J.; Becker, K.; Arolt, C.; Meder, L.; Zhao, Y.; Schloesser, H.; Baus, W. W.; Kamp, F.; Baues, C.; Beyer, A.; Odenthal, M.; Quaas, A.; Buettner, R.; Hillmer, A. M.

2025-02-01 cancer biology
10.1101/2025.01.28.635332 bioRxiv
Show abstract

Neoadjuvant chemoradiation therapy (RCT) is a frequently used treatment regimen for esophageal adenocarcinoma (EAC); however, the response varies dramatically, and resistance is a clinical challenge. We aimed to identify the molecular mechanisms underlying RCT resistance. We established a mouse xenograft RCT model with human EAC cell lines representing different response groups, and tested enhanced genomic instability as a potential evolutionary modulator by reducing BRCA2 function. Xenografts that relapsed after RCT displayed upregulation of stress response keratins, including KRT6 and KRT16 connected with a basal-like transcriptomic/ proteomic phenotype. We screened our cohort of 728 patients with EAC and found significantly shorter overall survival for patients with KRT6-high tumors, driven by patients receiving neoadjuvant treatment. Overall, we identified a basal-like cell state in EAC that reflects RCT relapse. The basal-like subtype is a marker of treatment failure, providing a new avenue for translational research to overcome RCT resistance.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.